Dr. Rob Rubens is a board-certified neurologist and a Fellow of the American Academy of Neurology, with over four decades of experience spanning clinical practice, academic medicine, and the pharmaceutical industry. A recognized expert in neurology clinical development, he has led programs across Parkinson’s disease, Alzheimer’s, epilepsy, psychiatric disorders, neuroimmunology, and rare CNS diseases.
Dr. Rubens played a pivotal role in the clinical development and FDA/EMA approval of Parkinson’s drugs, including RYTARY, NUMIENT, and most recently CREXONT. His extensive career includes leadership positions at Jazz Pharmaceuticals, Takeda, Impax (Amneal), and Pfizer, where he directed full-cycle drug development, from FIH to NDA, across small molecules, biologics, and gene therapies.
He is the founder of NeuroDevMA Consulting, providing clinical and medical affairs expertise to neurology-focused biotech firms and investors. Dr. Rubens holds an MD from Rutgers NJ Medical School and an MBA from the University of Washington. He is a Phi Beta Kappa and Alpha Omega Alpha honoree, and remains active in the scientific community through peer-reviewed publications, FDA advisory support, and scientific board service.